This study predates the use of newer treatments for T2DM such as sodium‐glucose‐co‐transporter‐2 inhibitors (several drugs of this class improve outcomes in HF, irrespective of the presence of T2DM20, 21, 22) and the GLP‐1 agonists and DPP‐4 inhibitors. The gene discussed is DPP4; the disease is hydrops fetalis.